All In Biotech

NDA 022047 · Cheplapharm

Seroquel Xr

Quetiapine Fumarate · Oral

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

May 17, 2007

Approved uses

6

Original approval plus efficacy supplements

Registered trials

398

129 Phase 3, 13 recruiting

FAERS reports

166,283

129,383 serious, 22,401 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1 )] . SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.2) ] ....

What it is approved for

From the label in effect Apr 10, 2026.

SEROQUEL XR is an atypical antipsychotic indicated for the treatment of: • Schizophrenia (1.1) • Bipolar I disorder, manic, or mixed episodes (1.2) • Bipolar disorder, depressive episodes (1.2) • Major depressive disorder, adjunctive therapy with antidepressants (1.3) 1.1 Schizophrenia SEROQUEL XR is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL XR in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6-week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13-17 years) treated with SEROQUEL [see Clinical Studies (14.1) ]. 1.2 Bipolar Disorder SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10 - 17 years) with manic episodes associated with bipolar I disorder treated with SEROQUEL [see Clinical Studies (14.2) ]. SEROQUEL XR is indicated for the acute treatment of depressive episodes associated with bipolar disorder. The efficacy of SEROQUEL XR was established in one 8-week trial in adults with bipolar I or II disorder and supported by two 8-week trials in adults with bipolar I or II disorder treated with SEROQUEL [see Clinical Studies (14.2) ]. SEROQUEL XR is indicated for the maintenance...

Mechanism: The mechanism of action of quetiapine in the listed indications is unclear. However, the efficacy of quetiapine in these indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2A (5HT 2A ) antagonism. The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D 2 , but greater activity at 5HT 2A receptors, than the parent drug (quetiapine).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • SEROQUEL XR · QUETIAPINE FUMARATE EQ 400MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • SEROQUEL XR · QUETIAPINE FUMARATE EQ 200MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • SEROQUEL XR · QUETIAPINE FUMARATE EQ 150MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • SEROQUEL XR · QUETIAPINE FUMARATE EQ 300MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • SEROQUEL XR · QUETIAPINE FUMARATE EQ 50MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Quetiapine" as an intervention, any sponsor and status, largest first.

All 398 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,887
  • off label use9,865
  • insomnia8,363
  • toxicity to various agents8,318
  • diabetes mellitus8,095
  • somnolence7,358
  • fatigue7,022
  • drug interaction6,787
  • weight increased6,710
  • anxiety6,689
  • nausea6,604
  • depression6,467

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,549
20051,921
20063,134
20075,530
20083,326
20097,688
20109,164
201110,170
201210,999
20134,481
20145,545
20157,047
20166,970
20178,436
20189,760
201910,016
202010,161
20219,134
20228,643
20238,868
20248,920
20258,430
20266,387

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Seroquel XR (Quetiapine Fumarate)

2024 spending

$7.5M

Beneficiaries

951

7,036 claims

Per beneficiary

$7,869

$18.88 per unit

View as table
YearSpending
2020$14,776,733
2021$12,146,599
2022$10,819,557
2023$9,338,118
2024$7,483,539

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,190 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.